Saturday 17 October 2026
Export ANGO’s income statement to Excel — free account
AngioDynamics, Inc.
ANGO Healthcare Medical Instruments & Supplies
AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025. In the quarter to August 2026, revenue grew 6.87%, EPS grew 35.0% and free cash flow grew 5.62%, each against the same quarter a year earlier.
11.25
0.33
−2.85%
Follow ANGO
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.75 | 1.51 | 1.42 | 2.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
115.60 | (151.94) | 25.96 | (44.21) | |
P/B ratio |
3.06 | 2.73 | 2.65 | 4.13 | |
Price to Tangible BV |
4.92 | 4.38 | 4.37 | 6.64 | |
EV/Sales |
1.80 | 1.56 | 1.42 | 2.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(98.55) | 110.06 | 146.97 | 190.22 | |
EV/FCF |
(42.07) | (214.05) | (138.33) | (297.81) | |
Quick Ratio |
1.20 | 1.26 | 1.37 | 1.32 | |
Current Ratio |
2.24 | 2.35 | 2.19 | 2.40 | |
Net Debt/EBITDA |
110.15 | 5.14 | 11.71 | 18.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.10 | 1.15 | 1.17 | 1.28 | |
Operating CF/Net income |
(0.73) | 0.38 | (1.53) | 2.16 | |
Capex/Depreciation |
(0.07) | (0.18) | (0.07) | (0.07) | |
Interest Coverage |
— | — | (34.56) | (82.98) | |
Research and Development Expense of Revenue |
9.78% | 9.03% | 9.44% | 9.86% | |
Selling, General and Administrative Expense of Revenue |
46.41% | 48.65% | 47.79% | 52.47% | |
Intangible Assets out of Total Assets |
0.25 | 0.25 | 0.25 | 0.26 | |
Share Based Compensation of Revenue |
3.64% | 3.42% | 4.52% | 5.56% | |
Graham Net Nets |
0.13 | 0.14 | 0.15 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.17%) | (6.60%) | (7.97%) | (4.83%) | |
Free Cash Flow Yield |
(2.43%) | (0.48%) | (0.72%) | (0.35%) | |
Revenue per Share |
1.91 | 1.89 | 2.09 | 1.93 | |
Operating CF per Share |
0.11 | (0.07) | 0.42 | (0.36) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.10 | (0.10) | 0.41 | (0.37) | |
Cash per Share |
1.00 | 0.91 | 1.30 | 0.81 | |
Shareholders Equity per Share |
4.24 | 4.17 | 4.11 | 3.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.24 | 4.17 | 4.11 | 3.90 | |
Free Cash Flow |
4.24 | (4.12) | 17.04 | (15.71) | |
Working Capital |
89.39 | 89.49 | 88.68 | 83.31 | |
Capital Expenditures |
(0.42) | (1.01) | (0.41) | (0.38) | |
Net Current Asset Value |
68.00 | 68.23 | 67.06 | 65.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
43.80 | 47.26 | 45.61 | 43.77 | |
Average Payables |
35.07 | 29.69 | 32.40 | 29.23 | |
Average Inventory |
65.74 | 60.84 | 57.22 | 58.60 | |
Average Assets |
280.62 | 273.05 | 273.65 | 253.79 | |
Average Common Equity |
181.55 | 179.61 | 176.90 | 171.41 |
Columns are period end dates · fundamentals updated 13 Oct 2026